Oral rabeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects.
BACKGROUND
Intravenous pantoprazole is often administered inappropriately to hospitalized patients who can take oral medications.


OBJECTIVE
To compare the antisecretory effects of oral rabeprazole and intravenous pantoprazole in healthy subjects.


METHODS
In a double-blind, double-dummy, two-way crossover study, 38 Helicobacter pylori-negative volunteers were randomized to oral rabeprazole 20 mg or intravenous pantoprazole 40 mg daily for 3 days followed, after a 14-day washout period by the comparator treatment. Intragastric pH was recorded continuously for 24 h at baseline and on days 1 and 3 of each treatment period.


RESULTS
The mean (95% CI) percentage of the 24-h recording with gastric pH >4 was higher with rabeprazole than with pantoprazole on day 1: 37.7% (30.6-44.8%) vs. 23.9% (20.0-27.8). The mean percentage times with pH >3 and >4 for all intervals assessed were greater and the median 24-h intragastric pH values were higher with rabeprazole than with pantoprazole on days 1 and 3. The mean acidity index was lower with rabeprazole on days 1 and 3.


CONCLUSIONS
Oral rabeprazole 20 mg produced greater acid suppression than intravenous pantoprazole 40 mg. Therefore, it may be an appropriate and effective alternative in patients who can take oral medication.
Armstrong
D
D
Division of Gastroenterology, McMaster University, Hamilton, ON, Canada. armstro@mcmaster.ca
James
C
C
Camacho
F
F
Chen
Y
Y
Horbay
G L A
GL
Teixeira
B
B
Husein-Bhabha
F A
FA
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000284:Administration, Oral; D000328:Adult; D000863:Antacids / Q000008:administration & dosage*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D006801:Humans; D006863:Hydrogen-Ion Concentration / Q000187:drug effects; D007262:Infusions, Intravenous; D008297:Male; D000077402:Pantoprazole; D064750:Rabeprazole
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000863:Antacids; D000897:Anti-Ulcer Agents; D064750:Rabeprazole; D000077402:Pantoprazole